Stocks & Investing
Thu, September 19, 2024
[ Thu, Sep 19th 2024
] - WOPRAI
Wed, March 6, 2024
[ Wed, Mar 06th 2024
] - WOPRAI
Fri, January 12, 2024
[ Fri, Jan 12th 2024
] - WOPRAI
Tue, October 31, 2023
[ Tue, Oct 31st 2023
] - WOPRAI
Tue, May 9, 2023
[ Tue, May 09th 2023
] - WOPRAI
Mon, March 6, 2023
[ Mon, Mar 06th 2023
] - WOPRAI
Fri, January 6, 2023
[ Fri, Jan 06th 2023
] - WOPRAI
Fri, October 28, 2022
[ Fri, Oct 28th 2022
] - WOPRAI
Wed, October 5, 2022
[ Wed, Oct 05th 2022
] - WOPRAI
Tue, August 2, 2022
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
Fri, May 6, 2022
[ Fri, May 06th 2022
] - WOPRAI
Wed, May 26, 2021
[ Wed, May 26th 2021
] - WOPRAI
Thu, November 5, 2020
[ Thu, Nov 05th 2020
] - WOPRAI
Thu, March 5, 2020
[ Thu, Mar 05th 2020
] - WOPRAI
Fri, November 1, 2019
[ Fri, Nov 01st 2019
] - WOPRAI
Adam Maeder Initiated (ABT) at Buy and Held Target at $131 on, Sep 19th, 2024
Adam Maeder of Piper Sandler, Initiated "Abbott Laboratories" (ABT) at Buy and Held Target at $131 on, Sep 19th, 2024.
Adam has made no other calls on ABT in the last 4 months.
There are 6 other peers that have a rating on ABT. Out of the 6 peers that are also analyzing ABT, 0 agree with Adam's Rating of Hold.
These are the ratings of the 6 analyists that currently disagree with Adam
- Raj Denhoy of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, August 27th, 2024
- Joanna Wiensch of "Citigroup" Maintained at Strong Buy with Increased Target to $127 on, Thursday, August 22nd, 2024
- Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $143 on, Monday, July 29th, 2024
- Vijay Kumar of "Evercore ISI Group" Maintained at Buy with Decreased Target to $120 on, Tuesday, July 2nd, 2024
- Shagun Singh of "RBC Capital" Reiterated at Buy and Held Target at $125 on, Tuesday, June 4th, 2024
- David Roman of "Goldman Sachs" Initiated at Strong Buy and Held Target at $121 on, Thursday, May 30th, 2024
